CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 612 enrolled
Drug / intervention
Fluticasone furoate/Vilanterol Inhalation Powder +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01165138
NCT01165138Phase 3Completed
CompareCT.gov

HZA106827: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Parallel Group Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder Alone in the Treatment of Persistent Asthma in Adults and Adolescents

GlaxoSmithKline·interventional·Posted Jul 19, 2010·Updated Feb 14, 2018

In Brief

A Phase 3 clinical trial evaluating Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, and 1 other intervention for Asthma. Completed, enrolled 612 participants across 70 sites in 6 countries.

Detailed Summary

The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesGermany, Japan, Poland, Romania, Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 19, 2010
Enrollment StartAug 20, 2010
Primary CompletionOct 1, 2011
Study CompletionOct 19, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.0 years ago

Interventions

Fluticasone furoate/Vilanterol Inhalation Powderdrug

Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks

Fluticasone Furoate Inhalation Powderdrug

Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks

Placebo Inhaltion Powderdrug

Placebo Inhaltion Powder inhaled orally once daily for 12 weeks